https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-12-01 / Int. J. Oncol. 2010 Dec;37(6):1439-522010-12-01 00:00:002021-11-15 16:59:47Transcriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-04 / Head Neck 2011 Oct;33(10):1394-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-04 / Head Neck 2011 Oct;33(10):1394-92010-11-04 00:00:002019-02-15 09:21:37Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-172010-11-01 00:00:002021-11-15 17:00:11Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Expert Rev Vaccines 2010 Nov;9(11):1275-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Expert Rev Vaccines 2010 Nov;9(11):1275-3022010-11-01 00:00:002019-02-15 09:21:43Use of attenuated paramyxoviruses for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-09-21 / Mol. Cancer Ther. 2010 Oct;9(10):2761-92010-09-21 00:00:002010-09-21 00:00:00Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-13 / Vaccine 2010 Oct;28(42):6891-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-13 / Vaccine 2010 Oct;28(42):6891-9002010-08-13 00:00:002021-11-15 17:00:34The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-62010-08-01 00:00:002019-02-15 09:21:46[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Surgery 2010 Aug;148(2):325-34
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Surgery 2010 Aug;148(2):325-342010-08-01 00:00:002010-08-01 00:00:00Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-62010-08-01 00:00:002019-02-15 09:21:42[Progress in using Newcastle disease virus for tumor therapy: a review]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-06-01 / J. Mol. Med. 2010 Jun;88(6):589-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-06-01 / J. Mol. Med. 2010 Jun;88(6):589-962010-06-01 00:00:002010-06-01 00:00:00Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer
